Prior treatment with Acthar in the past 2mos
Meet one of the above RA flare requirements
Subjects who have received live or live attenuated vaccines within 6 weeks prior to the first dose of study drug (or the zoster vaccine)

NCT02541955_exc_T1
Temporal
Prior
NCT02541955_exc_T2
Procedure
treatment
NCT02541955_exc_T3
Drug
Acthar
NCT02541955_exc_T4
Temporal
in the past 2mos
NCT02541955_exc_T5
Condition
RA flare requirements
NCT02541955_exc_T6
Multiplier
one of
NCT02541955_exc_T7
Drug
live attenuated vaccines
NCT02541955_exc_T8
Temporal
within 6 weeks prior to the first dose of study drug
NCT02541955_exc_T9
Reference_point
the first dose of study drug
NCT02541955_exc_T10
Multiplier
first dose
NCT02541955_exc_T11
Drug
study drug
NCT02541955_exc_T12
Drug
zoster vaccine
NCT02541955_exc_T13
Drug
ve o ccines w
NCT02541955_exc_T14
Scope
live or live attenuated vaccines